🚨 𝗬𝗼𝘂𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗗𝗲𝘀𝗶𝗴𝗻 𝗖𝗼𝘂𝗹𝗱 𝗕𝗲 𝗖𝗼𝘀𝘁𝗶𝗻𝗴 𝗬𝗼𝘂 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀! 🚨 Designing a trial for 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 is just one piece of the puzzle. If your study doesn’t 𝗮𝗹𝘀𝗼 meet payer requirements, reimbursement delays could stall your MedTech innovation’s success. 💡 Did you know? ✔ A 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝘁𝗿𝗶𝗮𝗹 may be necessary when competing against a lower-cost alternative ✔ 𝗡𝗼𝗻-𝗶𝗻𝗳𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝘁𝗿𝗶𝗮𝗹𝘀 can be the key to expanding indications and broadening reimbursement ✔ Without payer-aligned endpoints, your trial could fail to prove economic value—𝗲𝘃𝗲𝗻 𝘄𝗶𝘁𝗵 𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 At RQM+, we specialize in study designs that optimize reimbursement AND regulatory success. In our latest white paper, "𝗧𝗿𝗶𝗮𝗹𝘀 𝗧𝗵𝗮𝘁 𝗣𝗮𝘆," Jaishankar Kutty, Ph.D., Vice President, Global Regulatory Affairs and Margot Borgel, Ph.D., Director, IVD Global Regulatory Affairs, explore 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 where trial design directly impacted market access—and how to get it right. 📩 Download now and ensure your trial is built for success: https://lnkd.in/eQt3WkpA #MedTech #ClinicalTrials #MarketAccess #Reimbursement #HealthEconomics #MedicalDevices #RQMplus
